Table 3.
Open in new tab

Multiple Regression Analysis Evaluating esRAGE, IMT and PWV as Dependent Variables

Coefficient βP
esRAGE
    Multiple regression—model 1a
        Age, y−0.07<.001
        HbA1c, %−0.05.02
        BMI, kg/m2−0.007.04
    Multiple regression—model 2b
        Age, y−0.005<.001
        HbA1c, %−0.09.007
        hs-CRP, mg/dL−0.21.01
IMT
    Multiple regression—model 1a
        Age, y0.002<.001
        HbA1c, %0.03.01
    Multiple regression—model 2b
        Age, y0.003<.001
        HbA1c, %0.04.03
        esRAGE, ng/mL−0.06.001
PWV
    Multiple regression—model 1a
        Age, y0.025<.001
        Systolic BP, mm Hg0.015.01
    Multiple regression—model 2b
        Systolic BP, mm Hg0.02.001
        S100A12, ng/mL1.1.02
Coefficient βP
esRAGE
    Multiple regression—model 1a
        Age, y−0.07<.001
        HbA1c, %−0.05.02
        BMI, kg/m2−0.007.04
    Multiple regression—model 2b
        Age, y−0.005<.001
        HbA1c, %−0.09.007
        hs-CRP, mg/dL−0.21.01
IMT
    Multiple regression—model 1a
        Age, y0.002<.001
        HbA1c, %0.03.01
    Multiple regression—model 2b
        Age, y0.003<.001
        HbA1c, %0.04.03
        esRAGE, ng/mL−0.06.001
PWV
    Multiple regression—model 1a
        Age, y0.025<.001
        Systolic BP, mm Hg0.015.01
    Multiple regression—model 2b
        Systolic BP, mm Hg0.02.001
        S100A12, ng/mL1.1.02
a

Model 1 was adjusted for age, sex, smoking status, BMI, systolic BP, diastolic BP, HDL cholesterol, LDL cholesterol, non-HDL cholesterol, triglycerides, statin therapy, HbA1c, fasting glycemia, and insulin.

b

Model 2 was adjusted for sRAGE, esRAGE, WBC, S100A12, hs-CRP, and CML.

Table 3.
Open in new tab

Multiple Regression Analysis Evaluating esRAGE, IMT and PWV as Dependent Variables

Coefficient βP
esRAGE
    Multiple regression—model 1a
        Age, y−0.07<.001
        HbA1c, %−0.05.02
        BMI, kg/m2−0.007.04
    Multiple regression—model 2b
        Age, y−0.005<.001
        HbA1c, %−0.09.007
        hs-CRP, mg/dL−0.21.01
IMT
    Multiple regression—model 1a
        Age, y0.002<.001
        HbA1c, %0.03.01
    Multiple regression—model 2b
        Age, y0.003<.001
        HbA1c, %0.04.03
        esRAGE, ng/mL−0.06.001
PWV
    Multiple regression—model 1a
        Age, y0.025<.001
        Systolic BP, mm Hg0.015.01
    Multiple regression—model 2b
        Systolic BP, mm Hg0.02.001
        S100A12, ng/mL1.1.02
Coefficient βP
esRAGE
    Multiple regression—model 1a
        Age, y−0.07<.001
        HbA1c, %−0.05.02
        BMI, kg/m2−0.007.04
    Multiple regression—model 2b
        Age, y−0.005<.001
        HbA1c, %−0.09.007
        hs-CRP, mg/dL−0.21.01
IMT
    Multiple regression—model 1a
        Age, y0.002<.001
        HbA1c, %0.03.01
    Multiple regression—model 2b
        Age, y0.003<.001
        HbA1c, %0.04.03
        esRAGE, ng/mL−0.06.001
PWV
    Multiple regression—model 1a
        Age, y0.025<.001
        Systolic BP, mm Hg0.015.01
    Multiple regression—model 2b
        Systolic BP, mm Hg0.02.001
        S100A12, ng/mL1.1.02
a

Model 1 was adjusted for age, sex, smoking status, BMI, systolic BP, diastolic BP, HDL cholesterol, LDL cholesterol, non-HDL cholesterol, triglycerides, statin therapy, HbA1c, fasting glycemia, and insulin.

b

Model 2 was adjusted for sRAGE, esRAGE, WBC, S100A12, hs-CRP, and CML.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close